QuatSalts · New Quaternary Ammonium Salts for use in Drug Manufacture
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-03-01 → 2020-02-29
- EU contribution
- €774,000
- Participants
- 3
- Scheme
- MSCA-RISE
Lines connect the coordinator with its partners.
Results in brief
New Quaternary Ammonium Salts for use in Drug Manufacture
The problem being addressed: The ability to develop more environmentally friendly ways of manufacturing pharmaceuticals Why it's important for society: It is important so that pharmaceuticals can still be made, but with less harmful chemicals being employed in their manufacture which can have a deleterious impact on the environment What are the overall objectives: To develop, test and implement new catalysts which enable the environmentally friendly manufacture of drugs
Data: CORDIS, © European Union
Project objective
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop three new categories of quaternary ammonium salts to be used as catalysts for the cost-efficient and green manufacture of high value active pharmaceutical ingredients. In order to achieve this objective the proposal brings together 3 partners with complementary skills:University of Naples(UNIN): experts in the preparation and purification of cyclic peptides. Experts in solid phase synthesis and immobilisation of peptides on solid support.KelAda Pharmachem: Phase transfer catalysis/organo catalysis/scale-up of chemical processesUniversity of Linz(JKU Linz): experts in design of new ammonium salts and optimisation of enantioselective phase transfer catalyses. We have broken this proposal into the following separate Work Packages:WP1. Preparation of new designer ammonium salts [WP leader: Kelada]WP2. Preparation of cyclic peptide based ammonium salts [WP leader: UNINA]WP3. Evaluation of new ammonium salt catalysts prepared through WP1 [WP JKULinz]WP4. Evaluation of new Ammonium salt catalysts prepared through WP2[WP leader: UNINA]WP5. Application of Ammonium salts to drug production [WP leader: Kelada]WP6. Scale up of key steps or the manufacture of drugs [WP leader: Kelada]WP 7. Management, Communication & Dissemination [WP leader: KelAda]The above WP’s will be undertaken via a series of interlinked secondment of researchers between consortium partners and will be complemented by a series of training and other initiatives to facilitate interdisciplinary and intersectoral knowledge sharing and exchange.
Original text from CORDIS.
Participants
Links
Data: CORDIS, © European Union